Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer

Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer. First PARP inhibitor to...

Related Keywords

Japan ,United States ,United Kingdom ,Belgium ,Kenilworth ,Warwickshire ,Cambridge ,Cambridgeshire ,Canada ,Brussels ,Bruxelles Capitale ,London ,City Of ,Scotland ,American ,Daiichi Sankyo ,Andrew Tutt ,Roy Baynes ,Susan Galbraith ,King College London ,National Surgical Adjuvant Breast ,Union For International Cancer ,European Society For Medical Oncology Virtual Plenary ,Frontier Science Technology Research Foundation ,Nasdaq ,Merck Co Inc ,American Society Of Clinical Oncology Annual Meeting ,Company On Twitter Astrazeneca ,Breast International Group ,Astrazeneca ,Head Of Global Clinical Development ,American Cancer Society ,Development Agreement ,National Institutes Of Health ,Drug Administration ,Gynecologic Oncology Group ,Us National Cancer Institute ,Oncology Group ,Research Laboratories ,Investor Relations Team ,Institute Of Cancer Research ,International Breast Cancer Study Group Trials ,Radiation Therapy Oncology Group ,Olympia Phase ,European Society ,Medical Oncology Virtual ,Frontier Science ,Technology Research Foundation ,Clinical Oncology Annual Meeting ,New England Journal ,Global Chair ,Cancer Research ,College London ,Executive Vice President ,Senior Vice President ,Global Clinical Development ,Chief Medical Officer ,Cancer Institute ,National Institutes ,Bowel Project ,Southwest Oncology ,Cooperative Research ,Rare Diseases ,Adjuvant Treatment ,High Risk ,Primary Breast Cancer ,Accessed February ,Mutated Breast ,Cancer Statistics ,Mortality Worldwide ,Cancer Journal ,Breast Cancer Facts ,International Cancer ,Cancer Medicines ,Hazard Rates ,Breast Cancer During ,Results From ,Cellular Heterogeneity ,Breast Cancer ,Genome Stability ,Cancer Stemness ,Cancer ,